Top in ID: Novavax COVID-19 vaccine; threat of antimicrobial resistance
Click Here to Manage Email Alerts
Last week, the FDA authorized Novavax’s two-dose COVID-19 vaccine, expanding options in the United States.
In an ongoing clinical trial, researchers found that the Novavax vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19 among adults. In a subset of patients aged 65 years or older, it was 78.6% effective. The FDA’s announcement about the authorization was the top story in infectious disease last week.
Another top story was about a CDC report on how the COVID-19 pandemic has reversed a decade of progress against antimicrobial resistance. From 2019 to 2020, researchers found that resistant infections increased 15% among seven common pathogens.
Read these and more top stories in infectious disease below:
FDA authorizes Novavax’s COVID-19 vaccine, expanding options in US
The FDA issued an emergency use authorization for Novavax’s two-dose COVID-19 vaccine, making it the fourth COVID-19 vaccine available for use in the United States. Read more.
COVID-19 pandemic reversed years of progress against antimicrobial resistance
The COVID-19 pandemic reversed years of progress against antimicrobial resistance in the United States, with resistant hospital-onset infections and deaths both increasing at least 15% during the first year, according to a new CDC report. Read more.
Officials discuss making second COVID-19 boosters available to all US adults
The Biden administration confirmed that it has had discussions about making second COVID-19 booster shots available to all U.S. adults amid a surge in infections driven by the omicron BA.5 subvariant. Read more.
Mayo Clinic is second commercial lab to begin monkeypox testing
Mayo Clinic Laboratories became the second commercial laboratory in the U.S. to begin monkeypox testing as part of an effort to increase testing capacity and access. Read more.
Data show benefits of additional vaccine doses against omicron
A third or fourth dose of one of the COVID-19 messenger RNA vaccines offered increased protection among adults during the early omicron wave, according to data from more than 270,000 patients reported Friday in MMWR. Read more.